Trastuzumab deruxtecan (T-DXd) is approved in the United States and European Union for use in patients with HER2+ unresectable/metastatic breast cancer. Approval was based on the randomized, multicenter, open-label, phase III DESTINY-Breast03 (NCT03529110) trial.
In this interview we discuss with Dr Sara Hurvitz (David Geffen School of Medicine, UCLA Los Angeles, CA, USA) updated data from the prespecified overall survival analysis of the DESTINY-Breast03 trial. The primary objective of the trial was to compare the anti-tumor activity as well as the safety and efficacy of T-DXd versus trastuzumab emtansine (T-DM1) in HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane.
The abstract entitled ‘Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03’ was presented at San Antonio Breast Cancer Symposium (SABCS), 06–10, December, 2022.
- What is trastuzumab deruxtecan and what are its potential advantages over trastuzumab emtansine in patients with HER2+ unresectable/metastatic breast cancer? (0:15)
- Could you give us a brief overview of the DESTINY-Breast03 study and its interim efficacy and safety data? (2:08)
- What have been the findings of the overall survival analysis and the updated efficacy and safety analysis? (3:49)
- How clinically meaningful are these findings? (5:29)
- What will be the next steps in the clinical development of trastuzumab deruxtecan? (6:20)
Disclosures: Sara Hurvitz discloses grant/research support from Ambrx, Amgen, Arvinas, Astra Zeneca, Bayer, Cytomx, Daiichi-Sankyo, Dantari, Dignitana, Genentech/Roche, G1-Therapeutics, Gilead, GSK, Immunomedics, Eli Lilly, Macrogenics, Novartis, OBI Pharma, Orinove, Pfizer, Phoenix Molecular Designs, Ltd., Pieris, PUMA, Radius, Samumed, Sanofi, Seattle Genetics/Seagen and Zymeworks.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen.
Filmed as a highlight of SABCS 2022
Access more content on Breast Cancer
Share this Video
Related Videos In Breast Cancer
Angela DeMichele, ASCO 2023: The PALLAS trial, palbociclib with adjuvant endocrine therapy in patients with stage II-III breast cancer
The PALLAS trial assessed the efficacy of adding palbociclib to adjuvant endocrine therapy in patients with stage II-III breast cancer. In this touchONCOLOGY interview, we speak with Dr Angela DeMichele (Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA) to discuss the PALLAS trial and how it compares to the other CDK4/6 inhibitor adjuvant trials, […]
Sara Tolaney, ASCO 2023: Highlights from the NATALEE trial of ribociclib and endocrine therapy in the treatment of breast cancer
touchONCOLOGY spoke with editorial board member Sara Tolaney (Dana-Farber Cancer Institute, Boston, MA, USA) to discuss her highlights from the ASCO annual meeting. She highlights data from the NATALEE study (NCT03701334), which met its primary endpoint at interim analysis, thus showing clinically meaningful benefit for patients with early breast cancer. The abstract entitled ‘Ribociclib and […]
Sara Tolaney, ASCO 2023: Primary outcome analysis of the phase 3 SONIA trial and the final overall survival results from the phase 3 TROPiCS-02 study
touchONCOLOGY spoke with editorial board member Sara Tolaney (Dana-Farber Cancer Institute, Boston, MA, USA) to discuss her highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting, 2–6, June 2023. These include the phase 3 SONIA trial (NCT03425838) assessing CDK4/6 inhibitors for patients with HR+, HER2- advanced breast cancer, and the final overall survival […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!